125 related articles for article (PubMed ID: 27475989)
1. Complement triggers relocation of Mortalin/GRP75 from mitochondria to the plasma membrane.
Mazkereth N; Rocca F; Schubert JR; Geisler C; Hillman Y; Egner A; Fishelson Z
Immunobiology; 2016 Dec; 221(12):1395-1406. PubMed ID: 27475989
[TBL] [Abstract][Full Text] [Related]
2. Mortalin/GRP75 binds to complement C9 and plays a role in resistance to complement-dependent cytotoxicity.
Saar Ray M; Moskovich O; Iosefson O; Fishelson Z
J Biol Chem; 2014 May; 289(21):15014-22. PubMed ID: 24719326
[TBL] [Abstract][Full Text] [Related]
3. Cooperation between Hsp90 and mortalin/GRP75 in resistance to cell death induced by complement C5b-9.
Rozenberg P; Ziporen L; Gancz D; Saar-Ray M; Fishelson Z
Cell Death Dis; 2018 Feb; 9(2):150. PubMed ID: 29396434
[TBL] [Abstract][Full Text] [Related]
4. Regulation of Complement-Dependent Cytotoxicity by MicroRNAs miR-200b, miR-200c, and miR-217.
Hillman Y; Mazkereth N; Farberov L; Shomron N; Fishelson Z
J Immunol; 2016 Jun; 196(12):5156-65. PubMed ID: 27183614
[TBL] [Abstract][Full Text] [Related]
5. Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis.
Pilzer D; Fishelson Z
Int Immunol; 2005 Sep; 17(9):1239-48. PubMed ID: 16091382
[TBL] [Abstract][Full Text] [Related]
6. Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention.
Fishelson Z; Kirschfink M
Front Immunol; 2019; 10():752. PubMed ID: 31024572
[TBL] [Abstract][Full Text] [Related]
7. Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity.
Pilzer D; Saar M; Koya K; Fishelson Z
Int J Cancer; 2010 Mar; 126(6):1428-35. PubMed ID: 19739077
[TBL] [Abstract][Full Text] [Related]
8. Mortalin peptides exert antitumor activities and act as adjuvants to antibody-mediated complement-dependent cytotoxicity.
Jubran R; Saar-Ray M; Wawruszak A; Ziporen L; Donin N; Bairey O; Fishelson Z
Int J Oncol; 2020 Oct; 57(4):1013-1026. PubMed ID: 32700755
[TBL] [Abstract][Full Text] [Related]
9. Mortalin (GRP75/HSPA9) Promotes Survival and Proliferation of Thyroid Carcinoma Cells.
Starenki D; Sosonkina N; Hong SK; Lloyd RV; Park JI
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027376
[TBL] [Abstract][Full Text] [Related]
10. Elevated levels of mitochondrial mortalin and cytosolic HSP70 in blood as risk factors in patients with colorectal cancer.
Rozenberg P; Kocsis J; Saar M; Prohászka Z; Füst G; Fishelson Z
Int J Cancer; 2013 Jul; 133(2):514-8. PubMed ID: 23319326
[TBL] [Abstract][Full Text] [Related]
11. Emission of membrane vesicles: roles in complement resistance, immunity and cancer.
Pilzer D; Gasser O; Moskovich O; Schifferli JA; Fishelson Z
Springer Semin Immunopathol; 2005 Nov; 27(3):375-87. PubMed ID: 16189651
[TBL] [Abstract][Full Text] [Related]
12. Mortalin (HSPA9) facilitates
Wu PK; Hong SK; Chen W; Becker AE; Gundry RL; Lin CW; Shao H; Gestwicki JE; Park JI
Sci Signal; 2020 Mar; 13(622):. PubMed ID: 32156782
[TBL] [Abstract][Full Text] [Related]
13. Caveolin-1 and dynamin-2 are essential for removal of the complement C5b-9 complex via endocytosis.
Moskovich O; Herzog LO; Ehrlich M; Fishelson Z
J Biol Chem; 2012 Jun; 287(24):19904-15. PubMed ID: 22528500
[TBL] [Abstract][Full Text] [Related]
14. Mortalin-mediated and ERK-controlled targeting of HIF-1α to mitochondria confers resistance to apoptosis under hypoxia.
Mylonis I; Kourti M; Samiotaki M; Panayotou G; Simos G
J Cell Sci; 2017 Jan; 130(2):466-479. PubMed ID: 27909249
[TBL] [Abstract][Full Text] [Related]
15. Mortalin - a multipotent chaperone regulating cellular processes ranging from viral infection to neurodegeneration.
Flachbartová Z; Kovacech B
Acta Virol; 2013; 57(1):3-15. PubMed ID: 23530819
[TBL] [Abstract][Full Text] [Related]
16. Quantification of complement C5b-9 binding to cells by flow cytometry.
Moskovich O; Fishelson Z
Methods Mol Biol; 2014; 1100():103-8. PubMed ID: 24218253
[TBL] [Abstract][Full Text] [Related]
17. Restoration of p53 functions by suppression of mortalin-p53 sequestration: an emerging target in cancer therapy.
Shankaranarayana AH; Meduri B; Pujar GV; Hariharapura RC; Sethu AK; Singh M; Bidye D
Future Med Chem; 2023 Nov; 15(22):2087-2112. PubMed ID: 37877348
[TBL] [Abstract][Full Text] [Related]
18. Mortalin: present and prospective.
Kaul SC; Taira K; Pereira-Smith OM; Wadhwa R
Exp Gerontol; 2002; 37(10-11):1157-64. PubMed ID: 12470827
[TBL] [Abstract][Full Text] [Related]
19. Elimination of terminal complement complexes in the plasma membrane of nucleated cells: influence of extracellular Ca2+ and association with cellular Ca2+.
Carney DF; Hammer CH; Shin ML
J Immunol; 1986 Jul; 137(1):263-70. PubMed ID: 3711667
[TBL] [Abstract][Full Text] [Related]
20. Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells.
Starenki D; Hong SK; Lloyd RV; Park JI
Oncogene; 2015 Aug; 34(35):4624-34. PubMed ID: 25435367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
